NORTH CHICAGO, Ill., Nov. 21, 2014 /PRNewswire/ -- The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's (NYSE: ABBV) investigational, all-oral, interferon-free treatment of VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) with or without ribavirin (RBV) for patients with genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infection. The European Commission will review the opinions and make a final decision sometime in the first quarter of 2015.

NORTH CHICAGO, Illinois, Nov. 21, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park. The facility will expand the company's global operations for small molecule and biologics manufacturing, providing increased capacity for compounds within AbbVie's immunology and oncology pipelines. This reflects progress from AbbVie's announcement for manufacturing investment in Asia earlier this year.

NORTH CHICAGO, Ill., Nov. 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting (ASH), December 6-9, in San Francisco. Data will be highlighted in 13 accepted abstracts, including several oral presentations detailing new trial results from the venetoclax program in acute myelogenous leukemia, elotuzumab in multiple myeloma, and duvelisib in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.  

NORTH CHICAGO, Ill., Nov. 14, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.

NORTH CHICAGO, Ill., Nov. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA^® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 – 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.

BOSTON, Nov. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.

BOSTON, Nov. 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent  of genotype  4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR₁₂) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR₁₂ (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.

NORTH CHICAGO, Ill., Nov. 5, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2014 Healthcare Conference on Thursday, Nov. 13, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 10 a.m. Central time.

NORTH CHICAGO, Ill., Oct. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.

NORTH CHICAGO, Ill., Oct. 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than 5,000 respondents in the biotechnology, pharmaceutical and biopharmaceutical industries.